Objective Previous studies have suggested that intensive statin therapy, compared with moderate statin therapy, provided greater reduction of LDL and better protection against major cardiovascular events. However, the exact dose-dependent mechanism of plaque stabilization remains unclear. The aim of this study is to investigate the three-dimensional (3D) response of fibrous caps overlying lipid plaques to statin therapy.
Introduction
Previous studies have suggested that lipid-lowering therapy with statin reduces LDL and the risk of cardiovascular events [1] . The improved outcome is believed to be because of stabilization of vulnerable plaques. Optical coherence tomography (OCT) enables accurate assessment of fibrous cap thickness (FCT) [2] . Recent studies showed that statin therapy induced thickening of the fibrous cap (FC) [3, 4] . Komukai et al. [5] showed that 20 mg/day atorvastatin provided a greater increase in minimum FCT compared with 5 mg/day atorvastatin. However, the three-dimensional (3D) vascular response of FC to statin therapy is unknown. In this study, we investigated the 3D morphological change of FC using a novel 3D algorithm and compared the results with those generated by conventional methods in a randomly selected subset of patients from a larger prospective study (registered in http://www.ClinicalTrials.gov as NCT01023607) [6] .
Methods

Study design and participants
Eligible participants were statin-naive patients aged 18-75 years old with coronary artery disease. Study inclusion criteria were as follows: (a) at least one de-novo lesion with luminal diameter stenosis between 20 and 70% on coronary angiogram, (b) a lipid-rich plaque on OCT, and (c) LDL less than 160 mg/dl. The exclusion criteria were as follows: (a) life expectancy less than 12 months, (b) contraindication to atorvastatin or rosuvastatin, (c) creatinine level more than 2.0 mg/dl or end-stage renal disease, (d) severe hepatic dysfunction (aspartate aminotransferase and/or alanine transaminase > 3 times the upper limit of normal), and (e) congestive heart failure (left ventricular ejection fraction ≤ 35%). The patients who fulfilled the study criteria were assigned randomly (1 : 1 : 1) to receive atorvastatin 20 mg (AT20, moderate intensity), rosuvastatin 10 mg (RT10, moderate intensity), or atorvastatin 60 mg (AT60, high intensity) [7] for 12 months. OCT was performed at baseline, 6-, and 12-month follow-ups. Patients, study personnel, and study staff were blinded to treatment assignment. This protocol was approved by the institutional review board of Harbin Medical University. All patients provided informed consent before participation. Because the aim of this study is to compare the FC differences induced by high-intensity versus moderate intensity statin therapy, only patients treated with AT20 or AT60 for 1 year were selected randomly from the main study and included for this study.
OCT imaging and image analysis
All OCT procedures were performed after an intracoronary administration of 100-200 μg of nitroglycerin using either a time-domain optical coherence tomography (TD-OCT) system (M3 Cardiology Imaging System; LightLab Imaging Inc., Westford, Massachusetts, USA) or a frequency-domain optical coherence tomography (FD-OCT) system (C7-XR OCT Intravascular Imaging System; St Jude Medical, St Paul, Minnesota, USA). The study was carried out at Harbin Medical University between September 2009 and March 2013. All images were analyzed independently at the Massachusetts Institute of Technology and the Massachusetts General Hospital. The individual who analyzed the images was blinded to the clinical and treatment information.
Lipid plaques at baseline were identified on the basis of previously validated criteria on the presence of signalpoor regions with diffuse borders [8] . Lipid plaques at baseline and follow-ups were matched using side branches and/or calcifications. FCs were assessed using three different methods (Fig. 1) . First, conventional thinnest (minimum) fibrous cap thickness (tFCT) was assessed at each time point. Second, matched-segment FCT (mFCT) was assessed by measuring the matching site at 6 and 12 months corresponding to the tFCT region at baseline. The definitions and measurements of tFCT and mFCT are consistent with previous studies [2, 6] , respectively, but are named differently here to avoid confusion between each other. Third, the 3D morphology of FC was analyzed by segmenting the FC boundaries using a recently developed algorithm [9] . This algorithm enables determination of the thickness of the entire FC and generation of 3D metrics such as the FC surface area (SA), and was validated against three experienced human analysts [9] . Specifically, the algorithm requires the analyst to select the arc of each lipid plaque on a cross-sectional image (Fig. 2a) . On the basis of the lipid arc selection, the algorithm automatically computes the optimal FC boundaries by maximizing the intensity differences across the boundaries in the selected regions using a global optimization method (Fig. 2b ) [9] . The FC boundaries of all the frames where a lesion is present are segmented (Fig. 2c) . The analysts may adjust the boundaries if there was a segmentation error typically in case of luminal blood. On the basis of the segmentation, the computer algorithm automatically calculates a variety of volumetric metrics including the absolute FC SA in a thickness category (Fig. 2d) . For this study, we focused on the FC SA where FCT was less than 80 µm (SA < 80 µm ). The cut-off value was determined on the basis of previous in-vivo studies [10] . However, the measurement itself was intrinsically continuous as the thickness of all the points on the FC boundaries was determined. The segmented FCs were further rendered in 3D using a continuous colormap on the basis of their thickness for 3D visualization and assessment (Fig. 2d) . It should be noted that although the single-point analysis (e.g. mFCT) may be subject to difficulties of precisely matching the corresponding sites of FCs between baseline and follow-ups, the 3D measurement does not suffer from this limitation because FCs of the entire plaque were segmented and compared. For FD-OCT, if a plaque was blocked by the guidewire, only the blocking part was excluded from the analysis.
To assess interobserver variability of the FC SA measurement, 20 OCT pullbacks including data acquired by TD-OCT (M3; LightLab Imaging, n = 10) and FD-OCT (C7-XR; St Jude Medical Inc., n = 10) were analyzed by two independent analysts. The longitudinal location of the plaque was defined by the first analyst according to objective morphology of the plaque, but all algorithmrelated processes including Z-offset adjustment and segmentation of FC boundaries were carried out independently and blindly. To assess intraobserver variability, the same data were reanalyzed by the first analyst 2 weeks later.
Statistical analysis
Categorical data were compared using either a χ 2 -test or Fisher's exact test. Generalized estimating equations were used to compare measurements between groups to take into account the correlation among multiple plaques within a single patient. Intraobserver and interobserver agreement of the area measurement was evaluated by intraclass correlation coefficient. All statistical analyses were carried out using SPSS, version 17.0 (SPSS Inc., Chicago, Illinois, USA). A two-sided P-value less than 0.05 was considered statistically significant.
Results
A total of 31 lipid plaques (AT20 = 16, and AT60 = 15) from 21 patients (AT20 = 9 and AT60 = 12) were analyzed. There were no significant differences in the baseline characteristics between the two groups ( Table 1 ).
The laboratory findings are summarized in Table 2 . LDL was significantly reduced from the baseline to the 6-month follow-up in both treatment groups. There was no further significant reduction of LDL from the 6-to the 12-month follow-ups. Similar results were also observed for total cholesterol changes. There was no significant change in HDL from baseline to follow-ups.
3D FC SA where FCT was less than 80 µm (SA < 80 µm ) was assessed and compared with the conventional measurements including tFCT and mFCT (Fig. 3) . The intraobserver and interobserver agreement for assessing SA < 80 µm was 0.932 and 0.965 for TD-OCT cases and 0.956 and 0.929 for FD-OCT cases, respectively. There were significant increases in tFCT from baseline to 12 months for both groups (P = 0.005 for AT20, and P < 0.001 for AT60). However, the change was not significantly different between the two groups [43.2 µm; 95% confidence interval (CI): 13.2-73.2 µm for AT20 and 57.7 µm; 95% CI: 30.1-85.4 µm for AT60, P = 0.485, Fig. 3a ]. Significant increases in mFCT were observed in both groups, and the change from baseline to 12 months was greater in AT60 than in AT20 (P = 0.022) (Fig. 3b ). Significant decreases in SA < 80 μm were observed in AT60 (− 7.84 mm 2 ; 95% CI: − 10.07 to − 5.60 mm 2 , P < 0.001), but not in AT20 (− 2.58 mm 2 ; 95% CI: − 4.10 to − 1.06 mm 2 , P = 0.140). AT60 induced a significantly greater decrease in SA < 80 μm from the baseline to the 12-month follow-up (P < 0.001, Fig. 3c) . A complete comparison of the three measurements at the three time points is listed in Table 3 . Representative cases after 3D reconstructions show that the thin cap regions (red) presented as diverse patterns (scattered or confluent) in different locations at baseline (Fig. 4) . In the AT20 group, the overall SA < 80 μm became smaller; however, new spots with SA < 80 μm appeared at 12 months. In contrast, the AT60 group showed a marked improvement, with almost complete disappearance of SA < 80 μm .
Discussion
This is the first study to investigate the 3D morphological changes in FC in response to different intensities of statin therapy over time. The findings of this study have important clinical implications. Although the conventional methods (tFCT and mFCT) are useful, they suffer from sampling errors and are insufficient to explain the 3D remodeling of FC in response to statin therapy. The 3D measurements generated full segmentation of the FC boundaries, which enable a complete characterization of the FC morphology without requiring precise matching of the cross-sections of the plaque over time as required by the measurement of mFCT. In comparison, previous studies only evaluated FCT from single-point measurements. For example, Komukai et al. [5] . reported that the increase of tFCT was significantly greater with 20 mg/day compared with 5 mg/day of atorvastatin. Hou et al. [6] showed a greater increase of mFCT with 60 mg/day compared with 20 mg/day of atorvastatin. However, it is unclear how the 3D morphology of FC responds to different intensities of statin therapy. Our results complemented the previous studies, and further showed that intensive statin therapy led to greater reduction of thin cap SAs (SA < 80 μm ). This explains the lesion-level mechanisms behind previous clinical findings that intensive statin therapy lowers major adverse cardiovascular events. Although the intensities of statin therapy compared in this study may not be exactly the same as some of the previous studies, the conclusion is consistent. FCT is the most important determinant for plaque vulnerability [11] . Larger areas of thin cap directly translate into more vulnerable spots on a plaque. Therefore, the significant decrease of SA < 80 μm by intensive statin therapy may contribute directly toward the reduction of risks of plaque rupture. However, future clinical studies correlating the clinical outcomes of patients with 3D morphology of FC are needed to confirm this. In addition, 3D measurements are not only more sensitive for detecting differences in treatment effects but can also provide additional information on the patterns of FC, which is potentially an important factor for vulnerability.
It is conceivable that a plaque with a larger area of localized thin cap would be more vulnerable than a plaque with smaller scattered thin cap areas. Therefore, 3D measurements are preferred to better assess treatment effects and plaque vulnerability in future clinical studies.
The major limitation of this study is the small number of patients (n = 21). However, it is partially the purpose of this study to use a small number of patients to test the efficacy of various metrics. Despite the small number of patients, the representative 3D measurements such as SA < 80 μm changes between baseline and the 12-month follow-up were already significantly different between the treatment groups (P <0.001), supporting the value of the proposed 3D metrics. Second, two groups with the same kind of statin were selected out of three original studies as the third group was treated with a different kind of statin (rosuvastatin). Third, because of the limited follow-up duration, we did not assess the association between the 3D FC morphology and clinical outcome.
Conclusion
High-intensity statin therapy more effectively stabilized FCs at follow-up. The new 3D algorithm provided more comprehensive information on FC morphology and is more sensitive to detect the changes in plaque phenotype in response to statin therapy. Jang was supported by Michael A. Park and by Gill and Allan Gray. Zhao Wang and James G. Fujimoto were supported by National Institutes of Health (NIH) R01-CA075289-18 research grant.
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